Figure S1


A
K562
nilotinib (50 nmol/L)
dasatinib (10 nmol/L)
OP449 (μmol/L): — 1 2.5 — 1 2.5 — 1 2.5
p-BCR-ABL1
BCR-ABL1
p-STAT5
STAT5
p-ERK (42/44)
ERK (42/44)
α-Tubulin
B
K562
Cell Viability (% relative to untreated)
OP449 (μmol/L): — 0.25 1 — 0.25 1
ponatinib (1 nmol/L)
C
CML M-BP
(BCR-ABL1T315I; CML-02)
CFU-GM colonies (% relative to untreated)
OP449 (μmol/L): — 2.5 5 — 2.5 5
ponatinib (10 nmol/L)
D
CML CP
(CML-08)
Cell Viability (% relative to untreated)
OP449 (μmol/L): — 1 2.5 — 1 2.5
ponatinib (50 nmol/L)
E
CML L-BP
(CML-07)
Cell Viability (% relative to untreated)
OP449 (μmol/L): — 1 2.5 5 — 1 2.5 5
dasatinib (50 nmol/L)
F
CML M-BP
(BCR-ABL1T315I; CML-02)
% Annexin V-positive
OP449 (μmol/L): — 1 2.5 5 — 1 2.5 5
48hrs
72hrs